Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy

S. Barbaliscia,V. C. Di Maio,E. Teti,I. Lenci,M. Aragri, E. Polilli, Giuliana Fiorentino, V. Pace Palitti,B. Bruzzone, Silvia Paolucci, Niccolò Gabriele Coppola,T. Ruggiero,T. Pollicino, F. Niero,V. Micheli, L. A. Nicolini, S. Marenco, Asia Bertoli, Irene Maida,S. Francioso,L. Foroghi,V. Calvaruso,F. Morisco,A. Lleo,V. Boccaccio,A. Ciancio, R. Maserati,M. Puoti,M. Zazzi,B. Rossetti,Vincenzo Vullo, A. R. D’Ambrosio, L. Boglione,S. Bonora,S. Babudieri, G. Gubertini, Marilena Rendina,A. Pellicelli, V. Sangiovanni, Alessandro Ciaccio,G. Taliani, Giacomo Raimondo,G. B. Gaeta,A. Craxì, C. Pasquazzi,L. Sarmati,G. Parruti, M. Angelico,M. Andreoni, V. Cento,C. F. Perno,F. Ceccherini-Silberstein

Digestive and Liver Disease（2018）

引用 0|浏览18

暂无评分

摘要

Background and aims: Pan-genotypic direct-acting antivirals (DAA) will be the most used regimens. However, their use, in short, ribavirin-free regimens may be affected by the presence of resistance-associated-substitutions (RASs), whose prevalence varies within HCV-genotypes (GTs). This study investigated the resistance profile in HCV 2-3-4 infected, DAA-naïve and DAA-experienced, Italian patients.

查看译文

关键词

hcv,infected patients,resistance profiles,daa-experienced

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要